All Trials

Randomized Phase 2/3 Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous ovarian cancer (ECOG 0–1) and measurable disease, typically after bevacizumab, randomized to pegylated liposomal doxorubicin (PLD) with or without NP-G2-044 (prilukae), an oral first-in-class fascin (FSCN1) inhibitor targeting actin bundling/filopodia to reduce motility and potentially enhance antitumor immunity. Excludes primary platinum-refractory or platinum-sensitive disease, significant cardiac/QTc risk, active CNS disease, grade ≥2 neuropathy, severe GI dysfunction precluding oral therapy, extensive liver involvement, uncontrolled effusions/ascites, or prior severe PLD toxicity.

ClinicalTrials.gov ID: NCT07109414

A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with untreated metastatic pancreatic ductal adenocarcinoma harboring homozygous MTAP deletion or demonstrable MTAP loss are randomized to nab-paclitaxel/gemcitabine with or without BMS-986504, a selective MTA-cooperative PRMT5 inhibitor exploiting synthetic lethality in MTAP-deleted tumors. One induction cycle of nab-paclitaxel/gemcitabine before randomization is permitted if no progression or intolerable toxicity.

ClinicalTrials.gov ID: NCT07076121

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with mCRPC limited to bone and/or nodes (no visceral disease) who have progressed after ARPI, two taxanes (unless not feasible), PSMA-lutetium if available/appropriate, and PARP inhibitor if BRCA-mutated receive pasritamig plus best supportive care versus placebo plus best supportive care. Pasritamig is an investigational KLK2×CD3 bispecific T‑cell–redirecting antibody designed to target prostate-restricted KLK2 and engage T cells; ongoing ADT required, ECOG 0–2.

ClinicalTrials.gov ID: NCT07164443

A Phase II Study of Sequential Bipolar Androgen Therapy and ZEN-3694 in Sequence With Enzalutamide + ZEN-3694 in Asymptomatic Patients With Metastatic CRPC: The COSMYC Trial (COmbined Suppression of MYC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Asymptomatic men with metastatic castration‑resistant prostate cancer progressing after a next‑generation AR inhibitor (with ongoing ADT; prior taxane/PARP/radiopharmaceuticals allowed) receive sequential therapy starting with high‑dose testosterone plus the BET inhibitor ZEN‑3694 (targets BRD2/3/4/BRDT to suppress MYC/AR signaling), then transition at radiographic progression to enzalutamide plus ZEN‑3694. Aims to enhance disease control and potentially resensitize tumors to AR‑targeted therapy; key labs/organ function required, ECOG 0–2, PSA ≥1 ng/mL.

ClinicalTrials.gov ID: NCT06922318

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with metastatic castration-sensitive prostate adenocarcinoma (ECOG 0–1) who are ARPI- and chemotherapy-naïve in the mCSPC setting (allowing up to 3 months of ADT/first-generation antiandrogen) are randomized to enzalutamide plus the EZH2 inhibitor mevrometostat (PF-06821497) versus enzalutamide alone. Investigational agent mechanism: selective EZH2 (PRC2) inhibition to reduce H3K27 methylation and re-express silenced tumor suppressor genes.

ClinicalTrials.gov ID: NCT07028853

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Chemotherapy-naïve mCRPC adults (ECOG 0–1) who progressed on exactly one prior AR pathway inhibitor (enzalutamide, apalutamide, or darolutamide) and remain on castration are randomized to xaluritamig plus abiraterone versus investigator’s choice of abiraterone, docetaxel, or cabazitaxel. Xaluritamig (AMG 509) is a STEAP1×CD3 bispecific T‑cell engager designed to redirect T‑cell cytotoxicity; exclusions include prior abiraterone progression, prior STEAP1 therapy, mCRPC chemo, significant prior radionuclide/PSMA therapy, and neuroendocrine histology.

ClinicalTrials.gov ID: NCT07213674

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with mCRPC who have progressed on at least one next‑generation hormonal agent and 1–2 taxane regimens (ECOG 0–1) are randomized to the CYP11A1 inhibitor opevesostat (with physiologic steroid replacement) versus switching to abiraterone/prednisone or enzalutamide; efficacy will be evaluated separately in AR ligand‑binding domain mutation–positive and –negative cohorts. Prior PARP inhibitor or 177Lu‑PSMA‑617 is allowed; key exclusions include significant cardiovascular, thromboembolic, seizure, or endocrine risks and drug–drug interactions.

ClinicalTrials.gov ID: NCT06136624

PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with extensive-stage SCLC who have not progressed after induction platinum–etoposide plus durvalumab and have adequate tissue for central subtyping (A/N/I/P) and SLFN11 testing are randomized to durvalumab maintenance alone versus durvalumab plus a biomarker-directed agent: PARP1 inhibitor saruparib for subtype P or SLFN11+ A/N; ATR inhibitor ceralasertib for SLFN11– A/N; or NKG2A inhibitor monalizumab for subtype I. Treated, stable brain metastases allowed; leptomeningeal disease excluded.

ClinicalTrials.gov ID: NCT06769126

FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with untreated unresectable locally advanced or metastatic urothelial carcinoma with a qualifying FGFR3 genetic alteration (ECOG 0–2, measurable disease) are randomized to add oral vepugratinib (highly FGFR3-selective kinase inhibitor) versus oral placebo to first-line enfortumab vedotin (nectin-4–directed ADC) plus pembrolizumab (anti–PD-1). Key exclusions include prior systemic therapy for advanced/metastatic disease, baseline grade ≥2 neuropathy, uncontrolled/untreated CNS disease, and certain corneal/retinal disorders.

ClinicalTrials.gov ID: NCT07218380

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (including ER-low/HER2-negative) whose tumors are PD-L1–negative or otherwise ineligible for standard PD-(L)1 inhibitor plus chemotherapy receive physician’s choice chemotherapy (paclitaxel/nab-paclitaxel, gemcitabine/carboplatin, or eribulin). Patients are randomized double-blind to add pumitamig (BNT327), a bispecific anti–PD-L1/anti–VEGF-A antibody (checkpoint blockade plus anti-angiogenic therapy), versus placebo.

ClinicalTrials.gov ID: NCT07173751